Literature DB >> 26303319

Pathophysiology of Calcium, Phosphorus, and Magnesium Dysregulation in Chronic Kidney Disease.

Arnold J Felsenfeld1, Barton S Levine1, Mariano Rodriguez2.   

Abstract

Calcium, phosphorus, and magnesium homeostasis is altered in chronic kidney disease (CKD). Hypocalcemia, hyperphosphatemia, and hypermagnesemia are not seen until advanced CKD because adaptations develop. Increased parathyroid hormone (PTH) secretion maintains serum calcium normal by increasing calcium efflux from bone, renal calcium reabsorption, and phosphate excretion. Similarly, renal phosphate excretion in CKD is maintained by increased secretion of fibroblast growth factor 23 (FGF23) and PTH. However, the phosphaturic effect of FGF23 is reduced by downregulation of its cofactor Klotho necessary for binding FGF23 to FGF receptors. Intestinal phosphate absorption is diminished in CKD due in part to reduced levels of 1,25 dihydroxyvitamin D. Unlike calcium and phosphorus, magnesium is not regulated by a hormone, but fractional excretion of magnesium increases as CKD progresses. As 60-70% of magnesium is reabsorbed in the thick ascending limb of Henle, activation of the calcium-sensing receptor by magnesium may facilitate magnesium excretion in CKD. Modification of the TRPM6 channel in the distal tubule may also have a role. Besides abnormal bone morphology and vascular calcification, abnormalities in mineral homeostasis are associated with increased cardiovascular risk, increased mortality and progression of CKD.
© 2015 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26303319     DOI: 10.1111/sdi.12411

Source DB:  PubMed          Journal:  Semin Dial        ISSN: 0894-0959            Impact factor:   3.455


  35 in total

Review 1.  Phosphate Toxicity in CKD: The Killer among Us.

Authors:  Cynthia S Ritter; Eduardo Slatopolsky
Journal:  Clin J Am Soc Nephrol       Date:  2016-02-10       Impact factor: 8.237

2.  Hypermagnesemia in critically ill patients with cancer: A case report.

Authors:  Vijay Raju Krupesh; Hrishi Varayathu; Vinu Sarathy; Gogana Prabhakar Rao; Yogendra Shrestha; Radheshyam Naik
Journal:  Mol Clin Oncol       Date:  2021-04-21

3.  Pruritus and Patient Reported Outcomes in Non-Dialysis CKD.

Authors:  Nidhi Sukul; Elodie Speyer; Charlotte Tu; Brian A Bieber; Yun Li; Antonio A Lopes; Koichi Asahi; Laura Mariani; Maurice Laville; Hugh C Rayner; Bénédicte Stengel; Bruce M Robinson; Ronald L Pisoni
Journal:  Clin J Am Soc Nephrol       Date:  2019-04-11       Impact factor: 8.237

4.  Scaffolding kidney organoids on silk.

Authors:  Ashwani Kumar Gupta; Jeannine M Coburn; Jessica Davis-Knowlton; Erica Kimmerling; David L Kaplan; Leif Oxburgh
Journal:  J Tissue Eng Regen Med       Date:  2019-03-21       Impact factor: 3.963

5.  Disorders in bone-mineral parameters and the risk of death in persons with chronic kidney disease stages 4 and 5: the PECERA study.

Authors:  Pablo Molina; Mariola D Molina; Luis M Pallardó; Javier Torralba; Verónica Escudero; Luis Álvarez; Ana Peris; Pilar Sánchez-Pérez; Miguel González-Rico; María J Puchades; José E Fernández-Nájera; Elena Giménez-Civera; Luis D'Marco; Juan J Carrero; José L Górriz
Journal:  J Nephrol       Date:  2021-01-04       Impact factor: 3.902

Review 6.  Advances in Our Understanding of the Mechanism of Action of Drugs (including Traditional Chinese Medicines) for the Intervention and Treatment of Osteoporosis.

Authors:  Junjie Lu; Desheng Hu; Chen Ma; Bo Shuai
Journal:  Front Pharmacol       Date:  2022-06-14       Impact factor: 5.988

7.  Effect of variations in dietary Pi intake on intestinal Pi transporters (NaPi-IIb, PiT-1, and PiT-2) and phosphate-regulating factors (PTH, FGF-23, and MEPE).

Authors:  Tatiana Martins Aniteli; Flávia Ramos de Siqueira; Luciene Machado Dos Reis; Wagner Vasques Dominguez; Elizabeth Maria Costa de Oliveira; Patrícia Castelucci; Rosa Maria Affonso Moysés; Vanda Jorgetti
Journal:  Pflugers Arch       Date:  2018-01-25       Impact factor: 3.657

Review 8.  Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Leena Patel; Lisa M Bernard; Grahame J Elder
Journal:  Clin J Am Soc Nephrol       Date:  2015-12-14       Impact factor: 8.237

9.  State-of-the-Art Management of Hyperphosphatemia in Patients With CKD: An NKF-KDOQI Controversies Perspective.

Authors:  Julia J Scialla; Jessica Kendrick; Jaime Uribarri; Csaba P Kovesdy; Orlando M Gutiérrez; Elizabeth Yakes Jimenez; Holly J Kramer
Journal:  Am J Kidney Dis       Date:  2020-08-06       Impact factor: 8.860

10.  Association of mineral metabolism biomarkers with chronic kidney disease in Chinese adults.

Authors:  Jialin Li; Danni He; Wenjing Zhao; Xi'ai Wu; Minjing Luo; Ying Wang; Meihua Yan; Wenquan Niu; Ping Li
Journal:  Clin Exp Nephrol       Date:  2021-03-16       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.